Article
Oncology
Yu-Ting Hsieh, Bing-Juin Chiang, Chia-Chang Wu, Chun-Hou Liao, Chia-Da Lin, Chung-Hsin Chen
Summary: The study in Taiwanese mCRPC patients receiving enzalutamide revealed that high tumor burden (HTB) was associated with reduced PSA response rate, radiological response rate, and progression-free survival duration. HTB patients had lower disease control rate compared to low tumor burden (LTB) patients after treatment with enzalutamide.
Article
Oncology
Amir Goldkorn, Catherine Tangen, Melissa Plets, Gareth J. Morrison, Alexander Cunha, Tong Xu, Jacek K. Pinski, Sue A. Ingles, Timothy Triche, Andrea L. Harzstark, Manish Kohli, Gary R. MacVicar, Daniel A. Vaena, Anthony W. Crispino, David J. McConkey, Primo N. Lara, Maha H. A. Hussain, David I. Quinn, Nicholas J. Vogelzang, Ian Murchie Thompson, Neeraj Agarwal
Summary: The CellSearch CTC count can effectively predict the PSA levels within 7 months and progression-free survival within 2 years in mCSPC patients. Patients with undetectable CTCs have a higher chance of achieving favorable treatment outcomes.
CLINICAL CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
Yuta Kubota, Kazuhiro Tanaka, Masanori Kawano, Tatsuya Iwasaki, Ichiro Itonaga, Hiroshi Tsumura
Summary: In this study, a systematic review and meta-analysis were conducted to assess the surrogacy of intermediate end-points for overall survival (OS) in patients with rhabdomyosarcoma (RMS). The results showed a marginal correlation between event-free survival (EFS) and OS, but the surrogacy of EFS for OS cannot be confirmed.
SCIENTIFIC REPORTS
(2022)
Article
Multidisciplinary Sciences
Yuji Hakozaki, Yuta Yamada, Yuta Takeshima, Satoru Taguchi, Taketo Kawai, Masaki Nakamura, Takuya Iwaki, Taro Teshima, Yoshitaka Kinoshita, Yoshiyuki Akiyama, Yusuke Sato, Daisuke Yamada, Motofumi Suzuki, Haruki Kume
Summary: The study aimed to identify prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients and propose a new risk model. Clinical data of 102 mCRPC patients who received treatment between 2005 and 2018 at the University of Tokyo Hospital were retrospectively analyzed. The study found that low hemoglobin levels, short time to nadir PSA, and rapid PSA doubling time were independent prognostic factors for overall survival (OS).
SCIENTIFIC REPORTS
(2023)
Article
Urology & Nephrology
Scott A. Greenberg, Samuel L. Washington, Peter E. Lonergan, Janet E. Cowan, Avi S. Baskin, Hao G. Nguyen, Anobel Y. Odisho, Jeffry P. Simko, Peter R. Carroll
Summary: The study found that the presence of benign glandular tissue at the surgical margin after radical prostatectomy was not associated with an increased risk of malignancy at the surgical margin, detectable PSA, biochemical recurrence, or progression after detectable PSA.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Yushan Jia, Shuai Quan, Jialiang Ren, Hui Wu, Aishi Liu, Yang Gao, Fene Hao, Zhenxing Yang, Tong Zhang, He Hu
Summary: This study assessed the predictive value of magnetic resonance imaging (MRI) radiomics for progression-free survival (PFS) in patients with prostate cancer (PCa). The results showed that the hybrid model constructed from radiomics and clinical data performed the best in predicting PFS. This model provides a non-invasive diagnostic tool for risk stratification of clinical patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ayano Okabe, Haruto Hayashi, Hideki Maeda
Summary: This study examined the relationship between drug prices and their clinical efficacy and usefulness, using public information on anticancer drugs. The study found that drug prices were correlated with overall survival but not progression-free survival.
Article
Radiology, Nuclear Medicine & Medical Imaging
Matthew J. Roberts, Andrew Morton, Peter Donato, Samuel Kyle, David A. Pattison, Paul Thomas, Geoff Coughlin, Rachel Esler, Nigel Dunglison, Robert A. Gardiner, Suhail A. Doi, Louise Emmett, John Yaxley
Summary: Intraprostatic (68)Ga-PSMA-11 intensity is prognostic and may be a valuable new biomarker in localised prostate cancer, especially in men with biopsy-proven Gleason 3 + 4 disease considering an initial approach of active surveillance or focal therapy.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Oncology
Cedric Pobel, Edouard Auclin, Diego Teyssonneau, Brigitte Laguerre, Mathilde Cancel, Elouen Boughalem, Johanna Noel, Pierre Emmanuel Brachet, Denis Maillet, Philippe Barthelemy, Carole Helissey, Constance Thibault, Stephane Oudard
Summary: Cabazitaxel multiple rechallenges can be a treatment option in heavily pretreated patients with metastatic castration-resistant prostate cancer, with efficacy and manageable toxicity for those who had a good initial response to cabazitaxel.
Article
Radiology, Nuclear Medicine & Medical Imaging
Dong Yun Lee, Yong-il Kim
Summary: This study conducted a meta-analysis on the therapeutic effects of Ac-225-PSMA RLT in patients with mCRPC. The results showed that around 61% of patients had more than a 50% PSA decline and 84% of patients had any PSA decline. The common adverse events in Ac-225-PSMA RLT were xerostomia and severe hematotoxicity.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Oncology
Alex Qinyang Liu, Sebastiaan Remmers, Sui-Yan Lau, Siu-Ying Yip, Chi-Ho Leung, Christy Wing-Hin Mak, Chi-Hang Yee, Jeremy Yuen-Chun Teoh, See-Ming Hou, Monique Roobol, Chi-Fai Ng, Peter Ka-Fung Chiu
Summary: This study found that initial phi or phi density can predict the risk of future PCa in men with initial negative prostate biopsy. Men with higher baseline phi or phi density may require closer follow-up and repeated investigation, while those with lower phi or phi density may need less frequent follow-up.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Article
Medicine, Research & Experimental
Erolcan Sayar, Radhika A. Patel, Ilsa M. Coleman, Martine P. Roudier, Ailin Zhang, Pallabi Mustafi, Jin-Yih Low, Brian Hanratty, Lisa S. Ang, Vipul Bhatia, Mohamed Adil, Hasim Bakbak, David A. Quigley, Michael T. Schweizer, Jessica E. Hawley, Lori Kollath, Lawrence D. True, Felix Y. Feng, Neil H. Bander, Eva Corey, John K. Lee, Colm Morrissey, Roman Gulati, Peter S. Nelson, Michael C. Haffner
Summary: Prostate-specific membrane antigen (PSMA) expression is heterogeneous in metastatic castration-resistant prostate cancer (mCRPC), with some cases showing no detectable PSMA and others showing heterogeneous expression across metastases. Loss of PSMA is associated with epigenetic changes, including CpG methylation and loss of H3K27 acetylation at the FOLH1 locus. Treatment with HDAC inhibitors can reverse this repression and restore PSMA expression. These findings provide insights into PSMA expression patterns and regulation in mCRPC, and suggest a potential therapeutic strategy using epigenetic therapies to augment PSMA levels.
Article
Medicine, General & Internal
Po-You Chen, Shao-Ming Chen, Horng-Heng Juang, Chen-Pang Hou, Yu-Hsiang Lin, Pei-Shan Yang, Chien-Lun Chen, Phei-Lang Chang, Kuo-Yen Lin, Ke-Hung Tsui
Summary: The study found a correlation between prostate-specific antigen velocity (PSAV) and the surgical outcome of thulium laser enucleation of the prostate (ThuLEP), with a cutoff value of -0.52 ng/ml for PSAV to guide postoperative follow-up treatment at 3 months after benign prostatic hyperplasia (BPH) surgery.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, David M. Nanus, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Richard Wenstrup, Andrew J. Armstrong
Summary: PSMA-targeted radioligand therapy has significantly improved clinical outcomes in men with mCRPC. A liquid biopsy characterizing PSMA expression could be useful in guiding optimal therapy.
CLINICAL CANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Bisheng Cheng, Lingfeng Li, Yongxin Wu, Tianlong Luo, Chen Tang, Qiong Wang, Qianghua Zhou, Jilin Wu, Yiming Lai, Dingjun Zhu, Tao Du, Hai Huang
Summary: Prostate cancer is a major cause of cancer-related deaths in men globally. A study showed that RRM2 gene is associated with docetaxel resistance in prostate cancer by stabilizing ANXA1 expression and activating the PI3K/AKT pathway. Targeting RRM2 or ANXA1 may offer a promising therapeutic strategy to overcome docetaxel resistance in prostate cancer.
CELL AND BIOSCIENCE
(2023)